WEBULL
WebtradeDownload

How Pivotal Graves Trial Will Impact Biohaven Stock (BHVN)

Simply Wall St · 3d ago
  • Biohaven presented new clinical and preclinical data on its MoDE and TRAP degrader platforms and has begun enrolling a pivotal Phase 3 trial of BHV-1300 for Graves' disease, targeting autoantibodies in a condition that has not seen a new therapy approval in more than seventy years.
  • The firm coupled this clinical milestone with a US$80 million upfront licensing deal with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio in parts of Asia, adding non-dilutive funding while retaining rights in the United States, Europe and China.
  • The next step is to consider how Biohaven's investment narrative may be reshaped by this pivotal BHV-1300 program and degrader data.

Compare Biohaven's autoantibody degrader story with other potential breakout immunology plays by reviewing our hand-picked 35 healthcare AI stocks that are pushing the edge of tech-enabled drug development.

What Is Biohaven's Investment Narrative?

To own Biohaven, you need to buy into a high burn, high potential immunology and neurology platform where clinical execution matters more than current revenue. The BHV-1300 Phase 3 in Graves' disease, now enrolling globally, is the near term operational swing factor, with the ATA data and patient work sharpening the medical case for an autoantibody degrader. The Ono MoDE deal adds US$80 million of non dilutive cash plus potential milestones and royalties. This helps but does not remove the reality of a loss making business with less than a year of cash runway flagged by analysts.

Your decision is really about confidence in Biohaven's ability to turn MoDE and TRAP programs such as BHV-1300, BHV-1440 and BHV-1420 into registrational trials without exhausting the balance sheet. The stock has moved sharply over the past year while the company still reports zero revenue, a net loss of US$129.28 million in Q3 2026 and negative equity alongside prior dilution. In the short term, the pivotal Graves' readout path, future partnership appetite and any fresh financing steps remain the key catalysts and pressure points that this latest thyroid and nephrology data feeds into.

That said, before treating the degrader story as a straight shot higher, it is worth pausing on ...

There's only one way to know the right time to buy, sell or hold Biohaven. Head to Simply Wall St's company report for the latest analysis of Biohaven's Fair Value.

NYSE:BHVN 1-Year Stock Price Chart
NYSE:BHVN 1-Year Stock Price Chart

Exploring Other Perspectives

One alternate angle on Biohaven focuses on the most bullish revenue story. Top analysts were pencilling in US$287.7 million of revenue and US$45.8 million of earnings by 2029, with the stock trading on a P/E above 200x. That is a very optimistic setup. Use it as one extreme and explore a full range of views that may shift after this Graves’ data and Ono deal.

Explore another Biohaven fair value estimate, including one that suggests as much as 911% upside from the current price!

The Verdict Is Yours

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking For More Ideas Beyond Biohaven?

If the Biohaven story has sharpened your appetite for high conviction setups, it can help to line it up against other opportunities using a consistent framework. The Simply Wall St Screener lets you filter for specific traits so you are not just reacting to headlines but building a watchlist that actually fits your risk and return preferences.

  • If capital protection sits high on your priority list, start with a basket of companies that screen as relatively resilient by checking out 29 resilient stocks with low risk scores that score well on stability and risk metrics.
  • If you prefer businesses with less stressed finances, scan for stronger balance sheets and cleaner fundamentals through our curated list of solid balance sheet and fundamentals (24 results) to see which names clear those hurdles.
  • If you want to hunt for potential outliers, focus on under followed opportunities with robust fundamentals using a targeted 19 high quality undiscovered gems that surfaces quieter stories before they are widely discussed.